Leaker Brian R, O'Connor B, Hansel Trevor T, Barnes Peter J, Meng Lixen, Mathur Vandana S, Lieu Hsiao D
Pulmonology, Heart and Lung Centre, London, England.
J Nucl Cardiol. 2008 May-Jun;15(3):329-36. doi: 10.1016/j.nuclcard.2008.02.009. Epub 2008 Apr 14.
Patients with reactive airways are at risk for adenosine-induced bronchoconstriction, mediated via A(2B) and/or A(3) adenosine receptors.
To examine the effects of regadenoson, a selective adenosine A(2A) receptor agonist, on airway resistance, we conducted a randomized, double-blind, placebo-controlled crossover trial in asthmatic patients with a positive adenosine monophosphate challenge test. The mean ratio of the forced expiratory volume in 1 second (FEV(1)) at each tested time point relative to the baseline FEV(1) was significantly higher after treatment with regadenoson compared with placebo from 10 to 60 minutes after treatment. One patient had a substantial but asymptomatic FEV(1) reduction (-36.2%) after regadenoson that reversed spontaneously. The most common adverse events with regadenoson were tachycardia (66%), dizziness (53%), headache (45%), and dyspnea (34%). The mean heart rate significantly increased with regadenoson (maximum of +10.4 beats/min) versus placebo.
In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated.
反应性气道疾病患者存在因腺苷诱导支气管收缩的风险，这是通过A(2B)和/或A(3)腺苷受体介导的。
为了研究选择性腺苷A(2A)受体激动剂瑞加腺苷对气道阻力的影响，我们对磷酸腺苷激发试验阳性的哮喘患者进行了一项随机、双盲、安慰剂对照的交叉试验。与安慰剂相比，治疗后10至60分钟内，瑞加腺苷治疗后每个测试时间点的1秒用力呼气量（FEV(1)）相对于基线FEV(1)的平均比值显著更高。一名患者在使用瑞加腺苷后出现了显著但无症状的FEV(1)降低（-36.2%），随后自行恢复。瑞加腺苷最常见的不良事件是心动过速（66%）、头晕（53%）、头痛（45%）和呼吸困难（34%）。与安慰剂相比，瑞加腺苷使平均心率显著增加（最高增加10.4次/分钟）。
在这项针对48例对磷酸腺苷有支气管反应性的轻度或中度哮喘患者的初步安全性研究中，瑞加腺苷安全且耐受性良好。
